Professional Documents
Culture Documents
070674370805300610
070674370805300610
070674370805300610
Lonneke J van Nimwegen, MD1; Lieuwe de Haan, MD, PhD2; Nico JM van Beveren, MD3;
Mischa van der Helm, MSc4; Wim van den Brink, MD, PhD5; Don Linszen, MD, PhD6
Objective: To examine whether subjective well-being and craving for cannabis were
different in patients with schizophrenia or related disorders treated with either olanzapine
or risperidone.
Method: A 6-week, double-blind, randomized trial of olanzapine and risperidone was
carried out in 128 young adults with recent onset schizophrenia or related disorders.
Primary efficacy measures were the mean baseline-to-endpoint change in total scores on the
Subjective Well-Being under Neuroleptics scale, the Obsessive–Compulsive Drug Use
Scale, the Drug Desire Questionnaire, and the cannabis use self-report. An analysis of
covariance was used to test between-group differences.
Results: Estimated D2 receptor occupancy did not differ between olanzapine (n = 63) and
risperidone (n = 65). Similar improvements in subjective well-being were found in both
groups. In the comorbid cannabis-using group (n = 41, 32%), a similar decrease in craving
for cannabis was found in both treatment conditions.
Conclusions: Both olanzapine and risperidone were associated with improved subjective
well-being. No evidence was found for a differential effect of olanzapine or risperidone on
subjective experience or on craving for cannabis in dosages leading to comparable
dopamine D2 occupancy.
Clinical Trial Registration Number: ISRCTN46365995
Can J Psychiatry 2008;53(6):400–405
Clinical Implications
· Both olanzapine and risperidone are associated with improvements in subjective well-being in
adolescent patients with first psychosis.
· There is no preference for olanzapine or risperidone regarding improvement of subjective
well-being.
· There is no preference for olanzapine or risperidone regarding craving for cannabis.
Limitations
· Other antipsychotics might show similar results when prescribed in dosages with comparable
dopamine D2 receptor occupancy.
· The sample size of patients that used cannabis was small.
· Olanzapine and risperidone might have had a differential impact on craving for other
substances of abuse.
Thirty-one patients (22 %) discontinued treatment because of A limitation of the study is that only 41 of the 128 patients
adverse events (n = 9), lack of efficacy (n = 8), patient deci- were using cannabis at baseline, resulting in limited statisti-
sions (n = 10), or a combination of factors (n = 4), and 3 cal power for the detection of differences in changes in
patients (2%) were lost to follow-up. There were no signifi- craving and cannabis use. Another limitation is that only 64%
cant differences between the 2 treatment groups about age (25 of the eligible patients were willing to participate in the study,
years), sex (80% male), or diagnosis. Among the 128 random- possibly limiting the external validity of the study. However,
ized patients, 41 (32%) were using cannabis at baseline: 20 there were no significant differences in patients that refused
(49%) in the olanzapine and 21 (51%) in the risperidone group participation, compared with those who were randomized.
(P = 0.95). There were no significant differences in baseline Similar to many other studies among adolescents and young
characteristics between the patients using cannabis in the 2 adults with recent onset schizophrenia, only 70% of the par-
treatment conditions, except for the olanzapine group using ticipating patients completed the 6-week treatment. Whether
cannabis and having a significantly lower OCDUS score receiving olanzapine or risperidone, patients reported
(mean 19.3, SD 6.5) than the cannabis-using risperidone increased subjective well-being during the 6-week trial. The
group (mean 26.7, SD 10.3), P = 0.01. highest increase of subjective well-being took place in the
first week, which is consistent with previous findings. 4
Patients received a mean dosage of 9.8 mg olanzapine and
2.5 mg risperidone at 2 weeks, and 11.1 mg olanzapine and An explanation for the absence of differential effects is that
3.0 mg risperidone at 6 weeks. There was no significant dif- our hypothesis was incorrect. Perhaps the difference in dopa-
ference in estimated D2 receptor occupancy between the 2 mine dissociation between olanzapine and risperidone is too
groups. small to generate differences, or differences in dopamine dis-
sociation rate are not related to differences in subjective
After adjusting for SWN scores at baseline, there was no sig- experience or craving for cannabis. In recent placebo con-
nificant treatment by centre interaction effect (F3,119 = 1.5, P = trolled studies, risperidone showed decreases in crav-
0.22), and also none of the main effects were statistically sig- ing.30,31,35 Olanzapine showed a decrease27,36–37 and an
nificant (centre: F3,119 = 1.35, P = 0.26; treatment: F1,119 = increase in craving.28
0.037, P = 0.85). These results suggest there was no difference
between centres and treatment conditions. The largest More RCTs are needed to establish whether different types of
increase in SWN took place within the first week of the trial antipsychotics really differ in their effect on craving and drug
(Table 1). use behaviour of patients. In conclusion, in this double-blind
RCT, we found no evidence for a differential effect of
Within the group of patients using cannabis , after adjusting olanzapine and risperidone (in dosages that lead to compara-
for baseline scores, there were no significant group by centre ble dopamine D2 occupancy) on subjective well-being or on
interaction effects on the OCDUS (F2,33 = 0.28, P = 0.76) and craving for cannabis.
the DDQ (F2,32 = 1.67, P = 0.21), and none of the main effects
were statistically significant for the OCDUS (centre: F3,33 =
Funding and Support
1.50, P = 0.23; treatment: F1, 33 = 0.76, P = 0.39) and the DDQ
This study was funded by Eli Lilly. They were otherwise not
(centre: F3,32 = 1.50, P = 0.23; treatment: F1,32 = 0.93, P = involved in the design of the study, analyses, or interpretation of
0.34). These results suggest there was no difference in effect results. The manuscript was written solely by the listed authors.
on craving between centres or between treatments. Within the Dr de Haan and Dr Linszen received research funding from Eli
group of cannabis users, the reduction in the mean number of Lilly and Janssen Pharmaceuticals. Dr van den Brink received
funding from Merck, Tibotec, and Eli Lilly. Dr van Beveren
joints per week was not significantly different for olanzapine
received an unrestricted personal grant by Astra Zeneca
(mean 4.7, SD 9.8), compared with the risperidone group Company. Dr van Nimwegen and Mr van der Helm report no
(mean 4.3, SD 6.5), P = 0.16. competing interests.
Figure 1 Flow chart of a 6-week, double-blind RCT comparing olanzapine, 5 to 20 mg/day, to risperidone in
adolescents with recent onset schizophrenia or related disorders
Excluded (n = 63)
En rolment
Randomized (n = 138)
Olanzapine Risperidone
Alloaction
Lost to follow-up (no LOCF possible, no-show) Lost to follow-up (no LOCF possible, no-show)
(n = 1) (n = 2)
Follow-up
Table 1 Efficacy results at treatment endpoint for adolescent patients with first-episode psychosis who
received double-blind olanzapine or risperidone in a 6-week study
Patients included in ITT analyses
Acknowledgement 10. Kapur S, Seeman P. Does fast dissociation from the dopamine D 2 receptor
explain the action of atypical antipsychotics? A new hypothesis. Am J
We acknowledge Winfried Laan, Parnassia Medical Centre in The Psychiatry. 2001;158:360–369.
Hague, the Netherlands, and Eric Noorthoorn and Pieter de Wit, 11. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients’
Mediant Enschede, the Netherlands, for collecting data. subjective well-being under atypical antipsychotic drugs. Schizophr Res.
2001;50:79–88.
12. Mueser KT, Yarnold PR, Levinson DF, et al. Prevalence of substance abuse in
References schizophrenia: demographic and clinical correlates. Schizophr Bull.
1990;16:31–56.
13. Fowler IL, Carr VJ, Carter NT, et al. Patterns of current and life-time substance
1. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in
use in schizophrenia. Schizophr Bull. 1998;24:443–455.
schizophrenia: empirical and clinical findings. Schizophr Bull.
1997;23:637– 651. 14. Regier DA, Framer ME, Rae DS, et al. Comorbidity of mental disorders with
2. Van Putten T, May PR, Marder SR, et al. Subjective response to antipsychotic alcohol and other drug abuse. Results from the epidemiologic catchment area
drugs. Arch Gen Psychiatry. 1981;38:187–190. (ECA) study. JAMA. 1990;264:2511–2518.
3. Lambert M, Schimmelmann BG, Karow A, et al. Subjective well-being and 15. Soyka M, Albus M, Kathmann N, et al. Prevalence of alcohol and drug abuse in
initial dysphoric reaction under antipsychotic drugs—concepts, measurement schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci.
and clinical relevance. Pharmacopsychiatry. 2003;36:181–190. 1993;242:362–372.
4. Naber D, Karow A, Lambert M. Subjective well-being under the neuroleptic 16. Cleghorn JM, Kaplan RD, Szechtman B, et al. Substance abuse and
treatment and its relevance for compliance. Acta Psychiatr Scand Suppl. schizophrenia: effect on symptoms but not on neurocognitive function. J Clin
2005;427:29–34. Psychiatry. 1991;52:26–30.
5. Coldham EL, Addington J, Addington D. Medication adherence of individuals 17. Negrete JC, Knapp WP, Douglas DE, et al. Cannabis affects the severity of
with first episode of psychosis. Acta Psychiatr Scand. 2002;106(4):286 –290. schizophrenic symptoms: results of a clinical survey. Psychol Med.
6. Buhler B, Hambrecht M, Loffler W, et al. Precipitation and determination of the 1986;16:515–520.
onset and course of schizophrenia by substance abuse—a retrospective and 18. Linszen D, Dingemans PM, Lenior ME. Cannabis abuse and the course of
prospective study of 232 population-based first illness episodes. Schiz Res. recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994;51:273–279.
2002;54(3):243–251.
19. Dixon L, Haas G, Weiden P, et al. Acute effects of drug abuse in schizophrenic
7. Lambert M, Conus P, Lubman DI, et al. The impact of substance use disorders
patients: clinical observations and patients ’ self-reports. Schizophr Bull.
on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr
1990;16:69–79.
Scand. 2005;112:141–148.
8. de Haan L, Lavalaye J, Linszen D, et al. Subjective experience and striatal 20. Peralta V, Cuesta MJ. Influence of cannabis abuse on schizophrenic
dopamine D2 receptor occupancy in patients with schizophrenia stabilized by psychopathology. Acta Psychiatr Scand. 1992;85:127–130.
olanzapine or risperidone. Am J Psychiatry. 2000;157:1019–1020. 21. Brown ES, Nejtek VA, Perantie DC, et al. Cocaine and amphetamine use in
9. de Haan L, van Bruggen M, Lavalaye J, et al. Subjective experience and D 2 patients with psychiatric illness: a randomized trial of typical antipsychotic
receptor occupancy in patients with recent-onset schizophrenia treated with continuation or discontinuation. J Clin Psychopharmacol. 2003;23(4):384–388.
low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J 22. McEvoy JP, Freudenreich O, Levin ED, et al. Haloperidol increases smoking in
Psychiatry. 2003;160:303–309. patients with schizophrenia. Psychopharmacology. 1995;119:124–126.
23. de Haan L, Booij J, Lavalaye J, et al. Occupancy of dopamine D2 receptors by 35. De La Garza R, Newton TF, Kalechstein AD. Risperidone diminishes
antipsychotic drugs is related to nicotine addiction in young patients with cocaine-induced craving. Psychopharmacology. 2005;178:347–350.
schizophrenia. Psychopharmacology. 2006;183:500–505.
24. McEvoy J, Freudenreich O, McGee M, et al. Clozapine decreases smoking in 36. Smelson DA, Ziedonis D, Williams J, et al. The efficacy of olanzapine for
patients with chronic schizophrenia. Biol Psychiatry. 1995;37:550–552. decreasing cue-elicited craving in individuals with schizophrenia and cocaine
25. Green AI, Zimmet SV, Strous RD, et al. Clozapine for comorbid substance use dependence: a preliminary report. J Clin Psychopharmacol. 2006;26:9–12.
disorder and schizophrenia: do patients with schizophrenia have a
reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev
Psychiatry. 1999;6:287–296. 37. Hutchison KA, Swift R, Rohsenow DJ, et al. Olanzapine reduces urge to drink
26. Hutchison KE, Wooden A, Swift RM, et al. Olanzapine reduces craving for after drinking cues and a priming dose of alcohol. Psychopharmacology.
alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. 2001;155:27–34.
Neuropsychopharmacology. 2003;28:1882–1888.
27. Hutchison KE, Rutter MC, Niaura R, et al. Olanzapine attenuates cue-elicited
craving for tobacco. Psychopharmacology. 2004;175:407–413.
28. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of olanzapine for the Manuscript received June 2007, revised, and accepted October 2007.
treatment of cocaine dependence. Drug Alcohol Depend. 2003;70:265–273. Results were presented as a Poster Presentation at the 13th Schizophrenia
29. Sayers SL, Campbell EC, Kondrich J, et al. Cocaine abuse in schizophrenic Winter Workshop, Davos, Switzerland, February 4–10, 2006.
patients treated with olanzapine versus haloperidol. J Nerv Ment Dis. 1
Resident, Erasmus Medical Center, Rotterdam, the Netherlands;
2005;193:379–386.
30. Smelson DA, Losonczy MF, Davis CW, et al. Risperidone decreases craving and Resident, Academic Medical Center, University of Amsterdam, the
relapses in individuals with schizophrenia and cocaine dependence. Can J Netherlands.
2
Psychiatry. 2002;47:671–675. Senior Consultant, Adolescent Clinic of the Academic Medical Center,
31. Smelson DA, Williams J, Ziedonis D, et al. A double-blind placebo-controlled University of Amsterdam, the Netherlands.
3
pilot study of risperidone for decreasing cue-elicited craving in recently Psychiatrist, Erasmus Medical Center, Rotterdam, the Netherlands.
withdrawn cocaine dependent patients. J Subst Abuse Treat. 2004;27(1):45–49. 4
Clinical Psychologist, Parnassia Psycho Medical Center, The Hague, the
32. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, quality Netherlands.
of life, compliance and other clinical variables. Int Clin Psychopharmacol. 5
Professor, Amsterdam Institute for Addiction Research, Academic
1995;10:133–138.
Medical Center, Amsterdam, the Netherlands.
33. De Haan L, Weisfelt M, Dingemans PM, et al. Psychometric properties of the 6
subjective wellbeing under neuroleptics scale and the subjective deficit
Professor and Head, Adolescent Clinic of the Academic Medical Center,
syndrome scale. Psychopharmacology. 2002;162:24–28. University of Amsterdam, the Netherlands.
34. Franken IH, Hendriksa VM, van den Brink W. Initial validation of two opiate Address for correspondence: Dr LJ van Nimwegen, Erasmus Medisch
craving questionnaires the obsessive compulsive drug use scale and the desires Centrum, PO Box 2040, 3000 CA Rotterdam, the Netherlands;
for drug questionnaire. Addict Behav. 2002;27:675–685. 1.vannimwegen@erasmusmc.nl